Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Relationship Between the Tumor Markers and Interstitial Lung Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04597814
Recruitment Status : Completed
First Posted : October 22, 2020
Last Update Posted : October 23, 2020
Sponsor:
Information provided by (Responsible Party):
Zhang Jianheng, The First Affiliated Hospital of Guangzhou Medical University

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA125 are often increased in interstitial lung disease patients.

This study was undertaken to investigate the source of these serum tumor markers.


Condition or disease Intervention/treatment
the Relationship Between the Tumor Markers and Interstitial Lung Disease Patients Other: No Intervention

Detailed Description:

The serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA125 are often increased in interstitial lung disease patients.

This study was undertaken to investigate the source of these serum tumor markers.We hypothesis that these tumor markers are released from the lung.

The broncholveolr lvge fluid levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA125 were measured in the interstitial lung disease patients before lung transplantation. The immunohistochemical test was performed in the specimen lung after lung transplantation.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 13 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: The Relationship Between the Tumor Markers and Interstitial Lung Disease
Actual Study Start Date : January 1, 2019
Actual Primary Completion Date : October 15, 2020
Actual Study Completion Date : October 15, 2020

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
interstitial lung disease patients
interstitial lung disease patients who need lung transplantation
 Other: No Intervention
No Intervention
non- interstitial lung disease patients
non- interstitial lung disease patients who need thoracic surgery to remove pneumatocele
 Other: No Intervention
No Intervention


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. serum levels of carcinoembryonic antigen (CEA) [ Time Frame: 6months ]
    serum levels of carcinoembryonic antigen (CEA)

  2. serum levels of carbohydrate antigen 19-9 (CA19-9) [ Time Frame: 6months ]
    serum levels of carbohydrate antigen 19-9 (CA19-9)

  3. serum levels of carbohydrate antigen 125(CA125) [ Time Frame: 6months ]
    serum levels of carbohydrate antigen 125(CA125)

  4. The alveolar lavage fluid levels of carcinoembryonic antigen (CEA) [ Time Frame: 1 week ]
    The alveolar lavage fluid levels of carcinoembryonic antigen (CEA)

  5. The alveolar lavage fluid levels of carbohydrate antigen 19-9 (CA19-9) [ Time Frame: 1 week ]
    The alveolar lavage fluid levels of carbohydrate antigen 19-9 (CA19-9)

  6. The alveolar lavage fluid levels of carbohydrate antigen 125 [ Time Frame: 1 week ]
    The alveolar lavage fluid levels of carbohydrate antigen 125

  7. The lung tissue levels of carcinoembryonic antigen (CEA) [ Time Frame: 1 week ]
    The lung tissue levels of carcinoembryonic antigen (CEA)

  8. The lung tissue levels of carbohydrate antigen 19-9 (CA19-9) [ Time Frame: 1 week ]
    The lung tissue levels of carbohydrate antigen 19-9 (CA19-9)

  9. The lung tissue levels of carbohydrate antigen 125 [ Time Frame: 1 week ]
    The lung tissue levels of carbohydrate antigen 125


Biospecimen Retention:   Samples Without DNA
lung specimen after lung transplantation

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
lung disease patients for lung transplantation
Criteria

Inclusion Criteria

1.Interstitial lung disease patients for lung transplantation

-

Exclusion Criteria:

  1. tumor
  2. Interstitial lung disease patients could not be performed by lung transplantation
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04597814


Locations
Layout table for location information
China, Guangdong
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China, 520120
Sponsors and Collaborators
The First Affiliated Hospital of Guangzhou Medical University
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Zhang Jianheng, Principal Investigator, The First Affiliated Hospital of Guangzhou Medical University
ClinicalTrials.gov Identifier: NCT04597814    
Other Study ID Numbers: yilunshen2020145
First Posted: October 22, 2020    Key Record Dates
Last Update Posted: October 23, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Zhang Jianheng, The First Affiliated Hospital of Guangzhou Medical University:
carcinoembryonic antigen
carbohydrate antigen 19-9
carbohydrate antigen 125
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Interstitial
Respiratory Tract Diseases